OBJECTIVE: To investigate the associations between age, vascular health, and Alzheimer disease (AD) imaging biomarkers in an elderly sample. METHODS: We identified 430 individuals along the cognitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magnetic resonance imaging (MRI) scans from the population-based Mayo Clinic Study of Aging. A subset of 329 individuals had fluorodeoxyglucose (FDG) PET. We ascertained presently existing cardiovascular and metabolic conditions (CMC) from health care records and used the summation of presence/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke as a surrogate for vascular health. We used global amyloid from Pittsburgh compound B PET, entorhinal cortex tau uptake (ERC-tau) from tau-PET, and neurodegeneration in AD signature regions from MRI and FDG-PET as surrogates for AD pathophysiology. We dichotomized participants into CMC = 0 (CMC- ) versus CMC > 0 (CMC+ ) and tested for age-adjusted group differences in AD biomarkers. Using structural equation models (SEMs), we assessed the impact of vascular health on AD biomarker cascade (amyloid leads to tau leads to neurodegeneration) after considering the direct and indirect age, sex, and apolipoprotein E effects. RESULTS: CMC+ participants had significantly greater neurodegeneration than CMC- participants but did not differ by amyloid or ERC-tau. The SEMs showed that (1) vascular health had a significant direct and indirect impact on neurodegeneration but not on amyloid; and (2) vascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC-tau. INTERPRETATION: Vascular health had quantifiably greater impact on neurodegeneration in AD regions than on amyloid deposition. Longitudinal studies are warranted to clarify the relationship between tau deposition and vascular health. Ann Neurol 2017;82:706-718.
OBJECTIVE: To investigate the associations between age, vascular health, and Alzheimer disease (AD) imaging biomarkers in an elderly sample. METHODS: We identified 430 individuals along the cognitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magnetic resonance imaging (MRI) scans from the population-based Mayo Clinic Study of Aging. A subset of 329 individuals had fluorodeoxyglucose (FDG) PET. We ascertained presently existing cardiovascular and metabolic conditions (CMC) from health care records and used the summation of presence/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke as a surrogate for vascular health. We used global amyloid from Pittsburgh compound B PET, entorhinal cortex tau uptake (ERC-tau) from tau-PET, and neurodegeneration in AD signature regions from MRI and FDG-PET as surrogates for AD pathophysiology. We dichotomized participants into CMC = 0 (CMC- ) versus CMC > 0 (CMC+ ) and tested for age-adjusted group differences in AD biomarkers. Using structural equation models (SEMs), we assessed the impact of vascular health on AD biomarker cascade (amyloid leads to tau leads to neurodegeneration) after considering the direct and indirect age, sex, and apolipoprotein E effects. RESULTS:CMC+ participants had significantly greater neurodegeneration than CMC- participants but did not differ by amyloid or ERC-tau. The SEMs showed that (1) vascular health had a significant direct and indirect impact on neurodegeneration but not on amyloid; and (2) vascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC-tau. INTERPRETATION: Vascular health had quantifiably greater impact on neurodegeneration in AD regions than on amyloid deposition. Longitudinal studies are warranted to clarify the relationship between tau deposition and vascular health. Ann Neurol 2017;82:706-718.
Authors: Cynthia L Leibson; Allen W Brown; Jeanine E Ransom; Nancy N Diehl; Patricia K Perkins; Jay Mandrekar; James F Malec Journal: Epidemiology Date: 2011-11 Impact factor: 4.822
Authors: Elizabeth C Leritz; David H Salat; Victoria J Williams; David M Schnyer; James L Rudolph; Lewis Lipsitz; Bruce Fischl; Regina E McGlinchey; William P Milberg Journal: Neuroimage Date: 2010-10-28 Impact factor: 6.556
Authors: G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine Journal: Neurology Date: 2007-08-28 Impact factor: 9.910
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Rufus O Akinyemi; Elizabeta B Mukaetova-Ladinska; Johannes Attems; Masafumi Ihara; Raj N Kalaria Journal: Curr Alzheimer Res Date: 2013-07 Impact factor: 3.498
Authors: Cynthia L Leibson; Jack Needleman; Peter Buerhaus; John A Heit; L Joseph Melton; James M Naessens; Kent R Bailey; Tanya M Petterson; Jeanine E Ransom; Marcelline R Harris Journal: Med Care Date: 2008-02 Impact factor: 2.983
Authors: Prashanthi Vemuri; David S Knopman; Timothy G Lesnick; Scott A Przybelski; Michelle M Mielke; Jonathan Graff-Radford; Melissa E Murray; Rosebud O Roberts; Maria Vassilaki; Val J Lowe; Mary M Machulda; David T Jones; Ronald C Petersen; Clifford R Jack Journal: JAMA Neurol Date: 2017-06-01 Impact factor: 18.302
Authors: Prashanthi Vemuri; Val J Lowe; David S Knopman; Matthew L Senjem; Bradley J Kemp; Christopher G Schwarz; Scott A Przybelski; Mary M Machulda; Ronald C Petersen; Clifford R Jack Journal: Alzheimers Dement (Amst) Date: 2016-12-21
Authors: David S Knopman; Samantha Budd Haeberlein; Maria C Carrillo; James A Hendrix; Geoff Kerchner; Richard Margolin; Paul Maruff; David S Miller; Gary Tong; Maria B Tome; Melissa E Murray; Peter T Nelson; Mary Sano; Niklas Mattsson; David L Sultzer; Thomas J Montine; Clifford R Jack; Hartmuth Kolb; Ronald C Petersen; Prashanthi Vemuri; Megan Zoschg Canniere; Julie A Schneider; Susan M Resnick; Gary Romano; Argonde Corien van Harten; David A Wolk; Lisa J Bain; Eric Siemers Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Lisa Vermunt; Sietske A M Sikkes; Ardo van den Hout; Ron Handels; Isabelle Bos; Wiesje M van der Flier; Silke Kern; Pierre-Jean Ousset; Paul Maruff; Ingmar Skoog; Frans R J Verhey; Yvonne Freund-Levi; Magda Tsolaki; Åsa K Wallin; Marcel Olde Rikkert; Hilkka Soininen; Luisa Spiru; Henrik Zetterberg; Kaj Blennow; Philip Scheltens; Graciela Muniz-Terrera; Pieter Jelle Visser Journal: Alzheimers Dement Date: 2019-06-01 Impact factor: 21.566
Authors: Jennifer S Rabin; Hyun-Sik Yang; Aaron P Schultz; Bernard J Hanseeuw; Trey Hedden; Anand Viswanathan; Jennifer R Gatchel; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Vaishnavi Rao; Rachel F Buckley; Wai-Ying Wendy Yau; Dylan R Kirn; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal Journal: Ann Neurol Date: 2019-01-07 Impact factor: 10.422
Authors: Isabelle Bos; Stephanie J B Vos; Suzanne E Schindler; Jason Hassenstab; Chengjie Xiong; Elizabeth Grant; Frans Verhey; John C Morris; Pieter Jelle Visser; Anne M Fagan Journal: Alzheimers Dement Date: 2019-08-01 Impact factor: 21.566
Authors: Vijay K Ramanan; Scott A Przybelski; Jonathan Graff-Radford; Anna M Castillo; Val J Lowe; Michelle M Mielke; Rosebud O Roberts; Robert I Reid; David S Knopman; Clifford R Jack; Ronald C Petersen; Prashanthi Vemuri Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472